Fortress Biotech is a biotechnology business based in the US. Fortress Biotech shares (FBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.58 – an increase of 3.27% over the previous week. Fortress Biotech employs 101 staff and has a trailing 12-month revenue of around $57.7 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.58 |
|---|---|
| 52-week range | $1.33 - $2.89 |
| 50-day moving average | $1.62 |
| 200-day moving average | $1.81 |
| Wall St. target price | $15.33 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.69 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.53 from 2025-04-22
| 1 week (2025-04-17) | 1.53 |
|---|---|
| 1 month (2025-03-25) | -12.57% |
| 3 months (2025-01-24) | -15.93% |
| 6 months (2024-10-25) | -17.30% |
| 1 year (2024-04-25) | -11.05% |
|---|---|
| 2 years (2023-04-25) | -86.22% |
| 3 years (2022-04-22) | 15.75 |
| 5 years (2020-04-24) | 31.2 |
| Revenue TTM | $57.7 million |
|---|---|
| Gross profit TTM | $-20,085,000 |
| Return on assets TTM | -41.3% |
| Return on equity TTM | -1739.64% |
| Profit margin | -79.75% |
| Book value | $0.82 |
| Market Capitalization | $45.2 million |
TTM: trailing 12 months
We're not expecting Fortress Biotech to pay a dividend over the next 12 months.
Fortress Biotech's shares were split on a 1:15 basis on 9 October 2023 . So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Fortress Biotech shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Fortress Biotech shares which in turn could have impacted Fortress Biotech's share price.
Over the last 12 months, Fortress Biotech's shares have ranged in value from as little as $1.33 up to $2.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fortress Biotech's is 1.828. This would suggest that Fortress Biotech's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Fortress Biotech, Inc. , a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Emrosi, a minocycline hydrochloride extended-release capsules; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first- and second-degree burns, including sunburns, and radiation dermatitis. It also develops late-stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; UNLOXCYT for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; and BAER-101, a positive allosteric modulator. The company's preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc.
Track the progress of the S&P 500 stocks to make more informed investment decisions.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Stock lending allows investors to loan out their existing stocks, although it has both advantages and disadvantages.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.